Pharmaceutics (Jun 2022)

Milk Oral Lyophilizates with Loratadine: Screening for New Excipients for Pediatric Use

  • Sonia Iurian,
  • Cătălina Bogdan,
  • Ștefana Suciu,
  • Dana-Maria Muntean,
  • Lucia Rus,
  • Mihaela Berindeie,
  • Szidonia Bodi,
  • Rita Ambrus,
  • Ioan Tomuță

DOI
https://doi.org/10.3390/pharmaceutics14071342
Journal volume & issue
Vol. 14, no. 7
p. 1342

Abstract

Read online

The development of suitable formulations for the pediatric population remains a challenging field with great advances reported every year in terms of excipients and technology. When developing pediatric formulations, the acceptability of medicines represents a key element to consider. For this reason, milk can be a widely accepted excipient with taste-masking properties and supplementary advantages for drug solubility. In recent years, the orodispersible dosage forms have come onto the market as child-friendly formulations. The current study aimed to develop freeze-dried orodispersible dosage forms containing bovine milk or infant formulae as the main component. In the first stage, an exploratory study evaluated the mechanical properties of placebo milk formulations and the suitability of milk as a matrix-forming agent. As the appropriate mechanical strength to withstand manipulation was demonstrated, milk oral lyophilizates were loaded with a poorly soluble model API, loratadine. Hence, a D-optimal design was conducted to prepare milk lyophilizates with loratadine and to evaluate the effects of three factors (dose of loratadine, the lyophilizate size, and the type of milk) and their interactions. Finally, three formulations were prepared to confront the predictions of the DoE and further studied to thoroughly understand the observed effects. The experimental results showed the potential of milk in the development of oral lyophilizates loaded with different doses of suspended API.

Keywords